Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability